GlaxoSmithKline to invest HUF 18 bln in vaccine plant
The Hungarian unit of British drugmaker GlaxoSmithKline (GSK) will invest HUF 18 billion at its vaccine plant in Gödöllő, near Budapest, Minister of Foreign Affairs and Trade Péter Szijjártó said on Monday, according to Hungarian news agency MTI.
The government is supporting the investment, which will create 104 jobs, with a HUF 1.8 bln grant.
The plantʼs warehouse capacity will be expanded and a new unit producing pharmaceutical raw materials will be built, as a result of which the plantʼs output will triple, the minister said.
Christopher Hunley, managing director of GSK Biologicals, said the activity of the unit will be expanded as a result of the development and the plant will make components of diphtheria and tetanus vaccines for a new area of utilization.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.